Effect of maintenance therapy with dendritic cells: Cytokine-induced killer cells in patients with advanced non-small cell lung cancer

Tumori

Volumn 98, Issue 3, 2012, Pages 314-319

  Shi, Sheng Bin ^a   Ma, Ting Hang ^a   Li, Chun Hua ^a   Tang, Xiao Yong ^a  

^a LINYI PEOPLE'S HOSPITAL   (China)

Author keywords

Cytokine induced killer cells; Dendritic cells; Maintenance therapy; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DOCETAXEL; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL IMMUNOBIOLOGICAL CANCER THERAPY; DENDRITIC CELL IMMUNOBIOLOGICAL CANCER THERAPY; FEMALE; FEVER; HUMAN; IMPOTENCE; KIDNEY FUNCTION; LIVER FUNCTION; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; PATIENT SAFETY; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RESPIRATORY DISTRESS; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CYTOKINE-INDUCED KILLER CELLS; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; QUALITY OF LIFE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84867082350     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/1125.12398     Document Type: Article

References (22)

1. NSCLC Meta-Analyses Collaborative Group: Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol, 26: 4617-4625, 2008.
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. Cancer J Clin, 55: 10-30, 2005. (Pubitemid 40310185)
3. Yaman N, Ozgen A, Celik P, Ozyurt BC, Nese N, Coskun AS, Yorgancioglu A: Factors affecting the interval from diagnosis to treatment in patients with lung cancer. Tumori, 95: 702-705, 2009.
4. Thorne SH, Negrin RS, Contag CH: Synergistic antitumor effects of immune cell-viral biotherapy. Science, 311: 1780-1784, 2006.
5. Gunzer M, Jänich S, Varga G, Grabbe S: Dendritic cells and tumor immunity. Semin Immunol, 13: 291-302, 2001. (Pubitemid 32744580)
6. Whiteside TL, Odoux C: Dendritic cell biology and cancer therapy. Cancer Immunol Immunother, 53: 240-248, 2004. (Pubitemid 38328047)
7. Märten A, Greten T, Ziske C, Renoth S, Schöttker B, Buttgereit P, Schakowski F, von Rücker A, Sauerbruch T, Schmidt-Wolf IH: Generation of activated and antigenspecific T cells with cytotoxic activity after co-culture with dendritic cells. Cancer Immunol Immunother, 51: 25-32, 2002. (Pubitemid 34158520)
8. Baxevanis CN, Gritzapis AD, Tsitsilonis OE, Katsoulas HL, Papamichail M: HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes[J]. Int J Cancer, 98: 864-872, 2002. (Pubitemid 34286682)
9. Märten A, Ziske C, Schöttker B, Renoth S, Weineck S, Buttgereit P, Schakowski F, von Rücker A, Sauerbruch T, Schmidt-Wolf IG: Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother, 24: 502-510, 2001. (Pubitemid 33104869)
10. Goldie JH, Coldman AJ: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep, 63: 1727-1733, 1979. (Pubitemid 10138923)
11. Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Waterhouse DM, Bromund JL, Chen R, Hristova-Kazmierski M, Treat J, Obasaju CK, Marciniak M, Gill J, Schiller JH: Phase III study of immediate compared with delayed docetaxel after frontline therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol, 27: 591-598, 2009.
12. Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, Ciuleanu T, Cucevic B, Gyurkovits K, Ulsperger E, Jassem J, Grgic M, Saip P, Szilasi M, Wiltschke C, Wagnerova M, Oskina N, Soldatenkova V, Zielinski C, Wenczl M: Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer, 52: 155-163, 2006.
13. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K, Belani CP: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet, 374: 1432-1440, 2009.
14. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, Giaccone G: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol, 11: 521-529, 2010.
15. Zoll B, Lefterova P, Ebert O, Huhn D, Von Ruecker A, Schmidt-Wolf IG: Modulation of cell surface markers on NK-like T lymphocytes by using IL-2, IL-7 or IL-12 in vitro stimulation. Cytokine, 12: 1385 -1390, 2000.
16. Hackstein H, Thomson AW: Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol, 4: 24-34, 2004. (Pubitemid 38084129)
17. Yang XJ, Huang JA, Lei W, Zhu YB, Zhang XG: Antitumor effects of cocultured dendritic cells and cytokine-induced killer cells on lung cancer in vitro and in vivo. Ai Zheng, 25: 1329-1333, 2006.
18. Zhang S, Zhang SQ, Bai CX: The anti-tumor effects of dendritic cells co-cultured with cytokine-induced killer cells after chemotherapy. Zhonghua Jie He He Hu Xi Za Zhi, 27: 315-319, 2004.
19. Zhang S, Wang EZ, Bai CX, Xu YH: The proliferation profile in vitro and anti-tumor effects of dendritic cells co-culturing with CIK cells. Shi Yan Sheng Wu Xue Bao, 36: 375-380, 2003.
20. Wu C, Jiang J, Shi L, Xu N: Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res, 28: 3997-4002, 2008.
21. Zhao G, Huang Y, Ye L, Duan L, Zhou Y, Yang K, Ma Q, Lei Y, Song X, Huang M, Yang Y: Therapeutic efficacy of traditional vein chemotherapy and bronchial arterial infusion combining with ciks on III stage non-small cell lung cancer. Zhongguo Fei Ai Za Zhi, 12: 1000-1004, 2009.
22. Li H, Wang C, Yu J, Cao S, Wei F, Zhang W, Han Y, Ren XB: Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on nonsmall cell lung cancer in patients after surgery. Cytotherapy, 11: 1076-1083, 2009.